Literature DB >> 29485010

The Application of lncRNAs in Cancer Treatment and Diagnosis.

Yi Zhang1, Liling Tang1.   

Abstract

BACKGROUND: It is increasingly evident that lncRNAs have various biological functions playing as essential regulators, getting involved in diverse cellular processes. Many of the lncRNAs show aberrant expression in cancer, which is associated with different cancer types. The dysregulation of lncRNAs has been increasingly linked to cancer carcinogenesis and progression.
OBJECTIVE: Due to their tissue-specific expression and key role in cancer, lncRNAs have the potential to be novel biomarkers or effective drug targets for cancer. This review aims to present the application of lncRNAs in cancer diagnosis and targeted cancer therapies, elaborates molecular mechanisms and provides a deeper understanding of cancer-related lncRNA functions.
METHODS: Relevant recent patents are collected to summarize the application of lncRNAs in cancer. Combined with published articles, functions and mechanisms of lncRNAs are elaborated.
RESULTS: Patents revealed that a series of reagents and kits have been applied for early cancer diagnosis by detecting specific lncRNAs, having the advantages of high sensitivity, specificity and stability. In addition, lncRNAs as effective targets have been applied in developing targeted cancer drugs. With regard to their role in cancer, lncRNAs regulate target genes, thus to medicate cancer physiological and pathological processes through diverse mechanisms at epigenetic, transcriptional and posttranscriptional levels.
CONCLUSION: Current knowledge of lncRNAs presents prosperous prospects in cancer. However, functions of lncRNAs are still far from fully being understood. Therefore, further study is needed to advance imminent applications of these findings to the clinic. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cancer diagnosis; cancer treatment; epigenetic; long non-coding RNAs; post-transcriptional; transcriptional.

Mesh:

Substances:

Year:  2018        PMID: 29485010     DOI: 10.2174/1574892813666180226121819

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  43 in total

Review 1.  Cancer's epigenetic drugs: where are they in the cancer medicines?

Authors:  Sorayya Ghasemi
Journal:  Pharmacogenomics J       Date:  2019-12-10       Impact factor: 3.550

Review 2.  Diagnostic, prognostic and therapeutic potential of long noncoding RNAs in cancer.

Authors:  Muhammad Babar Khawar; Syeda Eisha Hamid; Tayyba Jan; Muddasir Hassan Abbasi; Muhammad Idnan; Nadeem Sheikh
Journal:  Mol Biol Rep       Date:  2022-01-24       Impact factor: 2.316

Review 3.  Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: An update of a systematic literature review.

Authors:  Samantha Goodman; Grace Chappell; Kathryn Z Guyton; Igor P Pogribny; Ivan Rusyn
Journal:  Mutat Res Rev Mutat Res       Date:  2021-12-09       Impact factor: 7.015

Review 4.  Potentials of long non-coding RNAs as biomarkers of colorectal cancer.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang; Jiarui Bao; Huahua Su
Journal:  Clin Transl Oncol       Date:  2022-05-17       Impact factor: 3.340

5.  The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer.

Authors:  Chunhui Liu; Yue Gao; Jiaxuan Ni; Saisai Chen; Qiang Hu; Can Wang; Mingjin Hu; Ming Chen
Journal:  BMC Cancer       Date:  2022-07-18       Impact factor: 4.638

6.  A machine learning framework that integrates multi-omics data predicts cancer-related LncRNAs.

Authors:  Lin Yuan; Jing Zhao; Tao Sun; Zhen Shen
Journal:  BMC Bioinformatics       Date:  2021-06-16       Impact factor: 3.169

7.  Long non-coding RNA LIFR-AS1 regulates the proliferation, migration and invasion of human thyroid cancer cells.

Authors:  Sha Li; Chen Wang; Yifang Lu; Weijuan Li
Journal:  3 Biotech       Date:  2021-03-22       Impact factor: 2.406

8.  Long Non-coding RNA CBR3 Antisense RNA 1 is Downregulated in Colorectal Cancer and Inhibits miR-29a-Mediated Cell Migration and Invasion.

Authors:  Mei Yang; Wenxi Chen; Haojie Liu; Liang Yu; Mingwu Tang; Yinghui Liu
Journal:  Mol Biotechnol       Date:  2022-02-02       Impact factor: 2.695

9.  Long non-coding RNA FAM230B is a novel prognostic and diagnostic biomarker for lung adenocarcinoma.

Authors:  Yu Cao; Hong Zhang; Jianming Tang; Rui Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

10.  Mechanism of tumor‑derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1.

Authors:  Chengluo Jin; Linmei Shi; Kunlun Li; Wei Liu; Yu Qiu; Yakun Zhao; Bai Zhao; Zhexun Li; Yifei Li; Qingguo Zhu
Journal:  Oncol Rep       Date:  2021-07-19       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.